
Sharekhan



Powered by the Sharekhan 3R Research Philosophy



What has changed in 3R MATRIX

	Old		New
RS		\Leftrightarrow	
RQ		\Leftrightarrow	
RV		\Leftrightarrow	

ESG Disclosure Score			NEW	
ESG RISK RATING Updated Mar 08, 2023			21.77	
Medi	um Ris	k		
NEGL	LOW	MED	HIGH	SEVERE
0-10	10 10-20 20-30 30-40			40+
Source: Morningstar				_

<u>j</u>

Company details

Market cap:	Rs. 4,837 cr
52-week high/low:	Rs. 3,000/1475
NSE volume: (No of shares)	0.58 lakh
BSE code:	523704
NSE code:	MASTEK
Free float: (No of shares)	1.9 cr

Shareholding (%)

Promoters	37.3
FII	13.3
DII	3.9
Others	45.6

Price chart



Price performance

(%)	1m	3m	6m	12 m
Absolute	-3.6	-6.7	-3.1	-43.6
Relative to Sensex	-6.3	-4.6	-3.9	-49.1
Sharekhan Research, Bloomberg				

Mastek Ltd

Decent Q4; Maintain Hold

IT & ITES		Sharekhan code: MASTEK		
Reco/View: Hold	\Leftrightarrow	CMP: Rs. 1,585 Price Target: Rs. 1,740		\mathbf{V}
1 L	lpgrade	\leftrightarrow Maintain 🛛 🗸	Downgrade	

Summary

- Mastek reported strong constant currency (CC) revenue growth of 5.3% q-o-q, beating our estimates of 1.8% cc revenue growth led by strong in-quarter execution and demand for Digital Engineering, Experience, and Cloud Transformation services.
- EBITDA margin improved 44 bps q-o-q to 17.7% but was slightly below our estimates of 17.9% driven by costoptimization focus but was offset by higher employee costs. 12 months order backlog was Rs 1,794.1 crore (\$218.3mn), up 5.2% in rupee terms and 4.1% in constant currency terms on q-o-q basis.
- With respect to US, the management mentioned that they have not seen any ramp down of new projects but admitted that they are seeing longer decision cycles. The management believes this trend is likely to stay for at least 2-3 quarters.
- We believe the outlook for FY24 looks uncertain in the near term given the incrementally deteriorating macro environment. Hence despite a decent quarter and strong order backlog, we maintain a Hold rating on Mastek with a revised PT of Rs. 1,740 as sustaining the momentum amidst uncertainty would be challenging. At CMP, the stock trades at 15.6x its FY2024E EPS and 13.2 its FY2025E EPS.

Mastek reported strong constant currency (CC) revenue growth of 5.3% q-o-q, beating our estimates of 1.8% cc revenue growth led by strong in-quarter execution and demand for Digital Engineering, Experience, and Cloud Transformation services. Revenue growth was aided by higher working days and currency movement during Q4. Revenues at Rs 709.2 crore was up by 22% on y-o-y basis and up 7.7% q-o-q. EBITDA margin improved 44 bps q-o-q to 17.7% but slightly below our estimates (17.9%) driven by cost-optimization focus but was offset by higher employee costs. Net profit came at Rs. 72.6 crore (up 13.1% q-o-q) and was 8.7% below our estimates owing to lower other income. 12-month order backlog was Rs 1,794.1 crore (\$218.3mn) as compared to Rs 1,705.8 crore (\$206.2 million) in Q3FY23, reflecting a growth of 5.2% in rupee terms and 4.1% in constant currency terms on Q-o-Q basis. Key market Europe witnessed strong growth, up 10.5% q-o-q while the third largest market, Middle East continued to grow steadily growing 8% q-o-q. However, softness was reflected in US which recorded flattish growth during the quarter. During Q4FY23, growth momentum was led by Government & Education, Financial Services and Healthcare which grew 11.9% / 10.7% and 6.4% q-o-q respectively. LTM attrition rate at 21% moderated by 230 bps q-o-q. Utilisation (%) (including trainees) improved to 73.8% from 69.3% in Q3FY23, up 450 bps. The management cited that in the UK while the environment is volatile the secure government services and core public sector service business is still resilient. With respect to US, the management mentioned that they have not seen any ramp down of new projects but admitted that they are seeing longer decision cycles. The management believes this trend is likely to stay for at least two to three quarters. We believe the outlook for FY24 looks uncertain in the near term given the incrementally deteriorating macro environment owing to the recent developments in its key Europe and US markets. Hence despite a decent quarter and s

Key positives

- Utilisation (%) (including trainees) improved to 73.8% from 69.3% in Q3FY23, up 450 bps.
- Contribution from Top 5 Clients improved by 150 bps to 29.6% from 28.1% q-o-q.
 - LTM Attrition moderated to 21% in Q4FY23 from 23.3% in Q3FY23 declining 230 bps q-o-q.
- Twelve-month order backlog was Rs 1,794.1 crore, up 5.2% q-o-q in rupee terms and 4.1% q-o-q in constant currency.

Key negatives

- Net reduction of 65 employees taking the headcount to 5622.
- Cash and Cash equivalents dropped to Rs 270 crore from Rs 324.9 crore in Q3FY23.

Management Commentary

- Management highlighted that they are continuing to diversify and see larger deals and opportunities in the areas where they are good which includes Oracle cloud, Salesforce business and UK public sector digital engineering business.
- The management stated that they have made some strong hiring not just at the leadership level but also at the
 account level and even the domain level in some cases. The capability investments that they have made will help
 them to position themselves better going forward in addition to getting the right people.
- Mastek cited that there is room for EBITDA margin improvement through different levers like utilization, subcon etc. They highlighted that they are comfortable with the 18% range and stated that they would look at improving the EBITDA margin to the 19-20% range. The management stated that they are looking at achieving growth some couple of percentage points above the industry growth.

 $Revision\ in\ estimates\ -$ We have fined-tuned our revenue/margin estimates for FY23/24/25 owing to macro headwinds.

Our Call

Valuation – Decent Q4, Maintain Hold: We believe the outlook for FY24 looks uncertain in the near term given the incrementally deteriorating macro environment owing to the recent developments in its key Europe and US markets. Hence despite a decent quarter and strong order back log we maintain a Hold rating on Mastek with a revised PT of Rs. 1,740 as sustaining the momentum amidst uncertainty would be challenging. At the CMP the stock trades at 15.6x its FY2024E EPS and 13.2 its FY2025E EPS.

Key Risks

Rupee appreciation and/or adverse cross-currency movements, slackening pace in deal closures, and/or constraints in local talent supply in the US would affect earnings.

Valuation (Consolidated)				Rs cr
Particulars	FY22	FY23	FY24E	FY25E
Revenue	2,183.8	2,563.4	2,735.1	3,004.5
OPM (%)	21.2	17.8	18.0	18.5
Adjusted PAT	295.1	267.7	318.0	378.6
% YoY growth	41.0	-9.3	18.8	19.1
Adjusted EPS (Rs)	103.4	86.6	101.9	120.2
P/E (x)	15.3	18.3	15.6	13.2
Р/В (х)	4.2	2.9	2.6	2.3
EV/EBITDA	9.2	10.8	9.8	8.3
ROE (%)	30.6	19.4	17.6	18.3
ROCE (%)	27.3	20.3	16.8	18.0

Source: Company; Sharekhan estimates

Key results highlights


- 12-month order backlog: 12 months order backlog at the end of Q4FY23 stood at Rs 1,794.1 crore (\$218.3mn) as compared to Rs 1,705.8 crore (\$206.2 mn) in Q3FY23, reflecting a growth of 5.2% in rupee terms and 4.1% in CC terms q-o-q and Rs 1,469.1 crore (\$193.8 million) in Q4FY22, reflecting growth of 22.1% in rupee terms and 17.2% in constant currency terms on y-o-y basis
- **Demand environment:** The management cited that in the UK while the environment is volatile the secure government services and core public sector service business is still resilient. Also, they stated that they have been helped by the higher number of working days and currency movement in Q4. With respect to US, the management mentioned that they have not seen any ramp down of new projects but admitted that they are seeing longer decision cycles. The management believes this trend is likely to stay for at least 2-3 quarters.
- **Trends across markets:** Key market Europe witnessed strong growth, up 10.5% q-o-q while the third largest market, Middle East continued to grow steadily growing 8% q-o-q. However, softness was reflected in US, which recorded flattish growth during the quarter.
- **Trends on verticals:** During Q4FY23, growth momentum was led by Government & Education, Financial Services and Healthcare which grew 11.9% / 10.7% and 6.4% q-o-q respectively while Manufacturing and Retail/Consumer saw muted growth growing 3.7% and 0.1% q-o-q respectively.]
- New accounts added: The company added 28 new clients in Q4FY23. Total active clients during Q4FY23 were 464 as compared to 444 in Q3FY23.
- Attrition moderates, Utilisation improves: Net reduction of 65 employees taking the headcount to 5622. LTM attrition rate at 21% moderated by 230 bps q-o-q. Utilisation (%) (including trainees) improved to 73.8% from 69.3% in Q3FY23, up 450 bps.
- Cash balance: The total cash, cash equivalents and fair value of Mutual Funds stood at Rs 270 crore as on March 31, 2023 as compared to Rs. 324.9 crore at the end of December 31, 2022. DSO improved in Q4FY23 to 93 compared to 98 days in Q3FY23. The company completed second tranche buyout of CCPS during the quarter.

Results (consolidated)					Rs cr
Particulars	Q4FY23	Q4FY22	Q3FY23	YoY (%)	QoQ (%)
Revenues In USD (mn)	86.3	77.2	80.1	11.7	7.7
Revenues In INR	709.2	581.5	658.7	22.0	7.7
Employee benefits expense	380.7	291.2	346.4	30.7	9.9
Other expenses	202.9	169.6	198.6	19.6	2.2
EBITDA	125.5	120.7	113.7	4.0	10.4
Depreciation & amortization	19.6	12.2	19.6	61.2	0.1
EBIT	105.9	108.5	94.1	-2.4	12.5
Other Income	-0.4	17.9	6.0	-102.3	-106.8
Finance costs	9.3	2.5	8.2	267.5	12.4
PBT	96.3	123.9	91.9	-22.3	4.7
Tax Provision	23.7	35.7	24.8	-33.7	-4.6
PAT	72.6	88.2	67.1	-17.7	8.1
Minority interest	0.0	-8.3	-2.9		
EO	0.0	0.0	0.0		
Net profit	72.6	79.9	64.2	-9.2	13.1
Adjusted net profit	72.6	79.9	64.2	-9.2	13.1
EPS (Rs)	23.5	26.1	20.9	-10.0	12.3
Margin (%)					
EBITDA	17.7	20.8	17.3	-305	44
EBIT	14.9	18.7	14.3	-373	65
NPM	10.2	13.7	9.7	-351	49
Tax rate	24.6	28.8	27.0	-423	-239

Source: Company, Sharekhan Research


Sharekhan

Mastek's constant-currency revenue growth trend (y-o-y)




Source: Company, Sharekhan Research






Source: Company, Sharekhan Research



Attrition trend (% q-o-q)


Source: Company, Sharekhan Research

Number of Fortune 1000 clients




Source: Company, Sharekhan Research





Source: Company, Sharekhan Research



Order booking (\$ mn) and growth (%)

Source: Company, Sharekhan Research

April 19, 2023

Outlook and Valuation

Sector view - Persisting multiple global headwinds turning outlook for FY24E uncertain

Owing to multiple global headwinds the outlook for FY24E looks uncertain, and the recovery could be gradual in the coming quarters. Hence, concerns relating to macro headwinds are unlikely to abate anytime soon thus restricting any material outperformance for Indian IT companies.

Company outlook - Long-term outlook intact

Mastek has created a consistent and predictable revenue stream from the UK's public sector over the past few years, thanks to the introduction of Digital Outcomes and Specialists (DoS) framework by the UK government (replacement of Digital Services-2 framework in 2016). Management indicated that revenue growth momentum in the UK public sector would continue in the coming quarters on account of higher spends on digital-transformation initiatives by UK government sector and addition of logos. Further, growth momentum in the US business is expected to accelerate because of strong demand for its integrated digital commerce solutions, increasing deal size, and new client additions.

Valuation - Decent Q4, Maintain Hold

We believe the outlook for FY24 looks uncertain in the near term given the incrementally deteriorating macro environment owing to the recent developments in its key Europe and US markets. Hence despite a decent quarter and strong order back log we maintain a Hold rating on Mastek with a revised PT of Rs. 1,740 as sustaining the momentum amidst uncertainty would be challenging. At the CMP the stock trades at 15.6x its FY2024E EPS and 13.2 its FY2025E EPS.



One-year forward P/E (x) band

Source: Sharekhan Research

About company

Established in 1982, Mastek provides IT services to five verticals – government (mostly caters to the UK government), retail, health, financial, and others. Mastek continues to be ranked among the top three vendors in delivering agile development services to the UK government on digital, G-Cloud, and GDS frameworks. The company primarily provides digital solutions to its retail and financial clients, while it helps the government to reduce cost and time in delivery in the UK. On the region front, the company is positioned largely in the UK and Europe, as 67.1% of its revenue comes from this region, followed by the US/ME/RoW with contribution to total revenue of 18.8%/9.2%/4.9%, respectively. During February 2020, the company acquired Evolutionary Systems (Evosys) through its subsidiaries, which provided access to new geographies as well as fast-growing segments.

Investment theme

Mastek has a long-standing relationship with the UK government as it was working as a subcontractor to large IT companies for execution of UK government's projects earlier. This long-term relationship and excellent execution capabilities make Mastek a prime beneficiary of UK government's digital spends. We expect strong order pipeline along with significant headroom for growth with the UK public sector (spend is ~GBP 12 billion), higher client mining of top accounts, and cross/up-sell opportunities to drive strong growth for Mastek going forward. Further, Mastek has been largely participating for digital contracts of UK public and private sector, where UK digital spending is growing at 30%. Mastek focuses on accelerating its revenue momentum in the US.

Key Risks

1) Rupee appreciation and/or adverse cross-currency movements, 2) constraint in local talent supply in the US would have an adverse impact on its earnings and 3) macro headwinds and possible recession in the US are likely to moderate the pace of technology spending.

Additional Data

Key management personnel

Hiral Chandrana	Global CEO
Abhishek Singh	President UK and Europe
Vijay Iyer	President Americas
Prameela Kalive	Chief Operating Officer
Arun Agarwal	Group CFO
Source: Company	

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Smallcap World Fund Inc	7.87
2	Capital Group Cos Inc	7.87
3	Vanguard Group Inc	2.33
4	Abakkus Growth Fund 1	1.51
5 Abakkus Emerging Opportunities Fund 1.49		1.49
6	6 ICICI Prudential Asset Management 0.72	
7	BlackRock Inc	0.61
8	Dimensional Fund Advisors LP	0.53
9	Norges Bank	0.31
10	Edelweiss Asset Management Ltd	0.20

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and detoriating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that neither he or his relatives or Sharekhan associates has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company and no part of the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either, SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Ms. Binkle Oza; Tel: 022-61169602; email id: complianceofficer@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com.

Registered Office: Sharekhan Limited, The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA, Tel: 022 - 67502000/ Fax: 022 - 24327343. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O/ CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183.

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.